Getronics Resets Business with Global Rebrand
Today, Getronics announces a global rebrand marking the culmination of months of work following its acquisition in July 2020.
The rebrand will make Getronics stand out in a crowded market, where it is already a leader in managed workplace services (*Gartner Magic Quadrant February 2020).
Getronics delivers end-to-end capabilities designed to build digital experiences that drive exceptional business outcomes. Getronics has over 2000 customers, including Credit Agricole, Intersnack, and Inditex, as well as Ford Motors, which the company has served for over 35 years.
“Our company is on a mission to harness technology to transform our clients’ businesses. Our rebrand gives us the opportunity to re-energise our entire organisation. We have not needed to buy anything or create anything new from scratch to do this, it was all there within our business,” says Kenton Fine, Executive Chairman. “Now we have brought it all together, with a new brand and clarity to our offering. It is hugely exciting for us, our talented teams, and our fantastic customers. We know this will give us the fuel to propel our organic growth and to ensure that our customers thrive.”
The rebrand, led by Getronics senior leadership team – CTO, Harsha Gowda, COO and Head of Global Delivery, Rogier Bronsgeest, Group Transformation Director, Andre Ribbens, Getronics CFO, Mike Field, and recently appointed CCO, Tom Regent – will enable the Getronics team, customers, and partners together to harness the power of technology and to revolutionise the digital experience, thereby transforming businesses and advancing communities.
“We have reimagined what our digital future might look like, not just for the team at Getronics, but for all of our clients. Our previous identity did not stand out in the way we wanted. Because of our journey of expansion, we had some legacy brands which were not distinct and did not clarify our offering. Our new identity, of which all of our 4000 colleagues have had a sneak preview, makes Getronics distinctive,” concludes Getronics CTO, Harsah Gowda.
Getronics offers the following integrated services: Digital Workplace, Cloud Services, Smart Spaces, Business Applications, Security & Compliance, Field & On-Site Support, Service Desk, and Network Services. Getronics now has a striking visual identity, distinguishing it in the marketplace, establishing the group’s role in reimagining a digital future for business.
-ENDS-
Executive services
Getronics has defined its offering under 8 services:
● Digital Workplace – an always-on, intuitive experience
● Cloud Services – public, private and on-premises
● Smart Spaces – transforming work spaces into smart spaces
● Business Applications – applications that build trust and loyalty
● Security & Compliance – delivering trust and peace of mind
● Field & On-Site Support - any device, any time, anywhere
● Service Desk – get reassurance and peace of mind
● Network Services - connecting people and applications
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005507/en/
Contact information
Media enquiries:
Nadia Gabbie
nadia.gabbie@getronics.com
+44 7973 177323
Stephanie Kronson
stephanie.kronson@getronics.com
+447931577367
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom